Thomas Reiser: Final Day as Executive Director – Closing a Remarkable Chapter at ISTH
Thomas Reiser, Executive Director at the International Society on Thrombosis and Haemostasis, shared a post on LinkedIn:
“Today is my final day as Executive Director at the International Society on Thrombosis and Haemostasis (ISTH).
I close this remarkable 14+ year chapter with immense gratitude for the trust placed in me, for the privilege of serving a mission and organization I believe so deeply in, and for the many extraordinary people who made this journey meaningful every step of the way.
To the ISTH team, Council, volunteers, members, partners, and the hashtag#thrombosis and hashtag#hemostasis community around the world: Thank you for allowing me to be part of this amazing community, the collaboration, dedication, and the friendships that will stay with me long after today.
I leave with great pride for all we have been able to accomplish together.
At the same time, I look forward to continuing to create impact, wherever the next chapter may lead me.
With heartfelt thanks and deep appreciation.”
Find more posts featuring Thomas Reiser on Hemostasis Today.
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis
-
Jan 12, 2026, 01:45Khurram Nasir on Where The Cholesterol Guidelines Are Headed
-
Jan 12, 2026, 01:35Nirav Dhanesha Shares The Lab’s Latest Publication on Neutrophil CD14 and DVT Link
-
Jan 12, 2026, 01:07Akshat Jain Presents The New Edition of Global Sickle Cell Disease Insight Publication
-
Jan 11, 2026, 21:05Simona Sacco Shares Expert Guidance for Clinicians on Minor Ischemic Stroke
-
Jan 11, 2026, 11:00Benjamin YQ Tan on Impacts of Early Cognitive and Psychological Statuses Post-Stroke
-
Jan 11, 2026, 10:46Salvador Payán Pernía: Leukodepletion Reduces Microplastic Burden in Red Blood Cell Concentrates
-
Jan 11, 2026, 10:36Mariasanta Napolitano on Pregnancy and Delivery Outcomes in Women with Hemophilia